Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AVTR, ARVN, ABBV, LLY, AZN, and represent 23.82% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: LLY (+$137M), AZN (+$115M), MRVI (+$97M), BMRN (+$87M), AVTR (+$56M), STTK (+$49M), ARNA (+$48M), CCXI (+$47M), DGX (+$47M), CAH (+$43M).
- Started 52 new stock positions in ARYA, LSAQ, NBIX, SIBN, ALBO, BLSA, ACAD, KNSA, PHAT, XLRN.
- Reduced shares in these 10 stocks: Pfizer Inc option (-$239M), Seattle Genetics (-$104M), , , TMO (-$52M), Rts/bristol-myers Squibb Compa (-$51M), BAX (-$50M), ANTM (-$47M), , BSX (-$37M).
- Sold out of its positions in ADAP, AKBA, AMRN, ANTM, AXSM, BAX, BLI, BIIB, BNTX, BSX.
- Avidity Partners Management was a net buyer of stock by $631M.
- Avidity Partners Management has $3.1B in assets under management (AUM), dropping by 42.87%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Companies in the Avidity Partners Management portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Avantor (AVTR) | 6.0 | $185M | +43% | 6.6M | 28.15 | |
| Arvinas Ord (ARVN) | 4.9 | $152M | +32% | 1.8M | 84.93 | |
| Abbvie (ABBV) | 4.7 | $145M | -10% | 1.4M | 107.15 | |
| Eli Lilly & Co. (LLY) | 4.4 | $137M | NEW | 811k | 168.84 | |
| Astrazeneca Sponsored Adr (AZN) | 3.7 | $115M | NEW | 2.3M | 49.99 | |
| Maravai Lifesciences Hldgs I Com Cl A (MRVI) | 3.1 | $97M | NEW | 3.4M | 28.05 | |
| Quest Diagnostics Incorporated (DGX) | 3.1 | $94M | +97% | 792k | 119.17 | |
| BioMarin Pharmaceutical (BMRN) | 2.8 | $87M | NEW | 993k | 87.69 | |
| Biohaven Pharmaceutical Holding (BHVN) | 2.8 | $87M | -21% | 1.0M | 85.71 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 2.8 | $86M | +25% | 1.2M | 73.15 | |
| Mirati Therapeutics (MRTX) | 2.7 | $84M | +38% | 380k | 219.64 | |
| I Mab Sponsored Ads (IMAB) | 2.4 | $75M | +18% | 1.6M | 47.15 | |
| Syndax Pharmaceuticals (SNDX) | 2.4 | $74M | +78% | 3.3M | 22.24 | |
| Biogen Idec Inc option Call Option | 2.0 | $61M | +15% | 248k | 244.86 | |
Setup an alertAvidity Partners Management will file the next quarterly 13-HR in about 1 months. Would you like to be notified? |
||||||
| Zentalis Pharmaceuticals (ZNTL) | 1.9 | $59M | +25% | 1.1M | 51.94 | |
| Change Healthcare (CHNG) | 1.9 | $58M | +21% | 3.1M | 18.65 | |
| Shattuck Labs (STTK) | 1.6 | $49M | NEW | 939k | 52.41 | |
| Natera (NTRA) | 1.6 | $48M | -4% | 480k | 99.52 | |
| Arena Pharmaceuticals Com New (ARNA) | 1.5 | $48M | NEW | 621k | 76.83 | |
| Chemocentryx (CCXI) | 1.5 | $47M | NEW | 757k | 61.92 | |
| Trillium Therapeutics Com New (TRIL) | 1.5 | $47M | +82% | 3.2M | 14.71 | |
| Apellis Pharmaceuticals (APLS) | 1.4 | $44M | +24% | 774k | 57.20 | |
| Cardinal Health (CAH) | 1.4 | $43M | NEW | 808k | 53.56 | |
| Organogenesis Hldgs (ORGO) | 1.3 | $42M | NEW | 5.5M | 7.53 | |
| Bausch Health Companies (BHC) | 1.3 | $41M | NEW | 2.0M | 20.80 | |
| Kadmon Hldgs (KDMN) | 1.3 | $40M | +5% | 9.6M | 4.15 | |
| Acceleron Pharma (XLRN) | 1.2 | $38M | NEW | 299k | 127.94 | |
| Sarepta Therapeutics (SRPT) | 1.2 | $37M | NEW | 217k | 170.49 | |
| Athira Pharma (ATHA) | 1.2 | $36M | 1.0M | 34.25 | ||
| Medtronic SHS (MDT) | 1.1 | $35M | +66% | 301k | 117.14 | |
| Catalent (CTLT) | 1.1 | $35M | +5% | 337k | 104.07 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.1 | $35M | NEW | 147k | 236.34 | |
| Anika Therapeutics (ANIK) | 1.1 | $33M | +21% | 731k | 45.26 | |
| Sigilon Therapeutics (SGTX) | 1.1 | $33M | NEW | 688k | 48.03 | |
| EXACT Sciences Corporation (EXAS) | 1.1 | $33M | NEW | 247k | 132.49 | |
| Essa Pharma Com New (EPIX) | 1.0 | $31M | +22% | 2.6M | 11.93 | |
| Cardiff Oncology (CRDF) | 0.9 | $29M | NEW | 1.6M | 17.99 | |
| Neurocrine Biosciences (NBIX) | 0.9 | $29M | NEW | 300k | 95.85 | |
| ACADIA Pharmaceuticals (ACAD) | 0.9 | $28M | NEW | 528k | 53.46 | |
| Aurinia Pharmaceuticals (AUPH) | 0.9 | $28M | -43% | 2.0M | 13.83 | |
| Zymeworks (ZYME) | 0.9 | $27M | +136% | 578k | 47.26 | |
| Blueprint Medicines (BPMC) | 0.9 | $27M | NEW | 240k | 112.15 | |
| Alphatec Hldgs Com New (ATEC) | 0.9 | $27M | NEW | 1.9M | 14.52 | |
| Bioxcel Therapeutics (BTAI) | 0.8 | $25M | 547k | 46.20 | ||
| AtriCure (ATRC) | 0.8 | $25M | NEW | 447k | 55.67 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.8 | $25M | +23% | 1.2M | 20.03 | |
| Sotera Health (SHC) | 0.6 | $19M | NEW | 700k | 27.44 | |
| Curis Com New (CRIS) | 0.6 | $19M | NEW | 2.3M | 8.19 | |
| Si-bone (SIBN) | 0.6 | $19M | NEW | 640k | 29.90 | |
| Dynavax Technologies Corp Com New (DVAX) | 0.6 | $18M | +97% | 4.0M | 4.45 | |
| Bellus Health Com New (BLU) | 0.6 | $18M | NEW | 5.7M | 3.06 | |
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 0.6 | $17M | NEW | 965k | 17.67 | |
| Intellia Therapeutics (NTLA) | 0.5 | $17M | NEW | 303k | 54.40 | |
| Alpine Immune Sciences (ALPN) | 0.5 | $16M | +54% | 1.2M | 12.60 | |
| Reata Pharmaceuticals Cl A (RETA) | 0.5 | $16M | NEW | 126k | 123.62 | |
| Surgery Partners (SGRY) | 0.5 | $15M | NEW | 531k | 29.01 | |
| Certara Ord (CERT) | 0.4 | $14M | NEW | 405k | 33.72 | |
| Sutro Biopharma (STRO) | 0.4 | $14M | NEW | 626k | 21.71 | |
| Codexis (CDXS) | 0.4 | $13M | NEW | 600k | 21.83 | |
| Harpoon Therapeutics (HARP) | 0.4 | $13M | -33% | 785k | 16.61 | |
| Olema Pharmaceuticals (OLMA) | 0.4 | $13M | NEW | 270k | 48.08 | |
| Oncosec Medical Incorporated (ONCS) | 0.4 | $13M | NEW | 2.0M | 6.45 | |
| Kura Oncology (KURA) | 0.4 | $11M | NEW | 348k | 32.66 | |
| Taysha Gene Therapies Com Shs (TSHA) | 0.3 | $10M | 392k | 26.54 | ||
| Castle Biosciences (CSTL) | 0.3 | $10M | NEW | 150k | 67.15 | |
| Aldeyra Therapeutics (ALDX) | 0.3 | $9.8M | 1.4M | 6.86 | ||
| Scynexis Com New (SCYX) | 0.3 | $9.6M | NEW | 1.3M | 7.65 | |
| Oak Street Health (OSH) | 0.3 | $9.2M | +50% | 150k | 61.16 | |
| Gritstone Oncology Ord (GRTS) | 0.3 | $8.4M | NEW | 2.1M | 3.94 | |
| Vesper Healthcare Acqstn Cor Unit 99/99/9999 (VSPRU) | 0.2 | $7.3M | 600k | 12.12 | ||
| Igm Biosciences (IGMS) | 0.2 | $7.1M | NEW | 80k | 88.29 | |
| Ligand Pharmaceuticals Com New (LGND) | 0.2 | $6.2M | NEW | 62k | 99.45 | |
| Cogent Biosciences (COGT) | 0.2 | $5.8M | NEW | 520k | 11.23 | |
| Outset Med (OM) | 0.2 | $5.7M | 100k | 56.84 | ||
| Bcls Acquisition Corp Com Cl A (BLSA) | 0.2 | $5.6M | NEW | 500k | 11.14 | |
| Arya Sciences Acquisition Com Cl A (ARYA) | 0.2 | $5.4M | NEW | 500k | 10.85 | |
| Ocular Therapeutix (OCUL) | 0.2 | $5.2M | NEW | 250k | 20.70 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.2 | $5.1M | 400k | 12.81 | ||
| Five Prime Therapeutics (FPRX) | 0.2 | $5.1M | NEW | 300k | 17.01 | |
| Phathom Pharmaceuticals (PHAT) | 0.2 | $5.1M | NEW | 153k | 33.22 | |
| Albireo Pharma (ALBO) | 0.2 | $4.7M | NEW | 125k | 37.51 | |
| Helix Acquisition Corp Com Cl A (HLXA) | 0.1 | $4.5M | NEW | 400k | 11.37 | |
| Lifesci Acquisition Ii Corp (LSAQ) | 0.1 | $4.3M | NEW | 400k | 10.67 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.1 | $3.8M | 300k | 12.76 | ||
| Bctg Acquisition Corp (BCTG) | 0.1 | $3.4M | 300k | 11.44 | ||
| Iteos Therapeutics (ITOS) | 0.1 | $3.1M | -71% | 93k | 33.82 | |
| Keros Therapeutics (KROS) | 0.1 | $2.8M | NEW | 40k | 70.55 | |
| Rocket Pharmaceuticals (RCKT) | 0.1 | $2.7M | NEW | 50k | 54.84 | |
| Annexon (ANNX) | 0.1 | $1.8M | +86% | 70k | 25.03 | |
| Accolade (ACCD) | 0.1 | $1.7M | 40k | 43.50 | ||
| Bioatla (BCAB) | 0.1 | $1.7M | NEW | 50k | 34.02 | |
| Nurix Therapeutics (NRIX) | 0.1 | $1.6M | 50k | 32.88 | ||
| American Well Corp Cl A (AMWL) | 0.0 | $1.3M | 50k | 25.34 | ||
| Relay Therapeutics (RLAY) | 0.0 | $1.2M | 30k | 41.57 | ||
| Inozyme Pharma (INZY) | 0.0 | $200k | -84% | 9.7k | 20.65 | |
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2020 Q4 filed Feb. 16, 2021
- Avidity Partners Management 2020 Q3 filed Nov. 16, 2020
- Avidity Partners Management 2020 Q2 filed Aug. 14, 2020
- Avidity Partners Management 2019 Q4 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 filed May 15, 2020
- Avidity Partners Management 2019 Q4 filed Feb. 14, 2020